Examining the Effect of Burosumab on Muscle Function
Diseases of the Musculoskeletal System
What is the purpose of this trial?
Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.
- Ages18 years - 65 years
- Trial withYale University School of Medicine
- Start Date02/13/2020
- End Date09/30/2023
- Last Updated11/11/2022
- Study HIC#2000026400